Friday, 26 April 2024 03:40 PM
OR
Login using
Enrollment begins for Sanofi and GSK Phase 3 efficacy trial of COVID-19 vaccine candidate in Nepal, led by IVI
September 28, 2021 16:07 pm
KATHMANDU, Sept 28: Sanofi and GSK have received approval for their Phase 3 clinical study in Nepal to assess the safety, efficacy and immunogenicity of their adjuvant recombinant-protein COVID-19 vaccine candidate.
Trending
Just In
- Police disclose identity of seven individuals arrested with almost 2 kg gold and more than Rs 10 million in cash
- NIMSDAI Foundation collaborates with local govt for Lobuche Porter’s Accommodation Project
- Home Ministry directs recalling security personnel deployed for personal security against existing laws
- Fake Bhutanese refugee case: SC orders continued pre-trial detention for seven individuals including former DPM Rayamajhi
- ADB Vice-President Yang pays courtesy call on PM Dahal
- PM Dahal, Chairman of CIDCA Zhaohui hold meeting
- MoFAGA transfers 8 under secretaries and 11 section officers (with list)
- PM Dahal arrives in Morang